肝癌患者血清IGF-Ⅱ水平与AFP的关系

Relationship Between Levels of Serum IGF-Ⅱ and AFP in Patients with Primary Hepatic Cancer

目的 :探讨原发性肝癌 (PHC)患者血清IGF -Ⅱ水平及临床意义。方法 :采用放射免疫分析法检测PHC和肝硬化患者血清IGF -Ⅱ和AFP含量 ,并与正常对照组进行比较。结果 :PHC组血清IGF -Ⅱ水平明显高于正常对照组 (p<0 0 1) ,阳性检出率为 78 9%、特异性为 6 1 7%、诊断有效率为 4 8 7% ;肝硬化组亦明显高于正常对照组 (p<0 0 1) ,但与肝癌组比较则明显降低 (p <0 0 1) ,阳性检出率为 6 7 7%。结论 :血清IGF -Ⅱ测定有助于PHC和肝硬化患者病情观察和预后判断 ,IGF -Ⅱ和AFP联检可以相互补充 ,提高PHC的阳性检出率 。

Objective To study the level of serum IGF-Ⅱ in patients with primary hepatic cancer(PHC) and its significance. Methods Levels of serum IGF-Ⅱ and AFP were detected in patients with PHC(n=38), cirrhosis(n=31) and 30 controls by radioimmunoassay. Results Levels of serum IGF-Ⅱ in patients with PHC were significantly higher than those in normal controls ( p <0 01). The positive rate of IGF-Ⅱ was 78 9%, the specificity was 61 7% and the effective rate of diagnosis was 48 7%. Levels of IGF-Ⅱ in patients with cirrhosis were higher than those in normal controls ( p <0 01), but were lower than those in patients with liver cancer significantly ( p <0 01), and the positive rate of IGF-Ⅱ was 67 7%. Conclusion The detection of serum IGF-Ⅱ may be of help to judge the severity of the liver disease and evaluate the patient's prognosis. The detection of both serum IGF-Ⅱ and AFP would be complementary, especially in those PHC patients with negative AFP.